Ceftriaxone has a therapeutic role in Alexander disease

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 2, 2010, Pages 416-417

  Sechi, GianPietro ^a   Balbi, Pietro ^b   Bachetti, Tiziana ^c   Matta, Manuela ^a   Serra, Alessandro ^d   Deiana, Giovanni A ^a   Di Zanni, Eleonora ^c   Ceccherini, Isabella ^c  

^a UNIVERSITY OF SASSARI   (Italy)

^b IRCSS   (Italy)

^c G GASLINI INSTITUTE   (Italy)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; ASPARTIC ACID; CEFTRIAXONE; GLIAL FIBRILLARY ACIDIC PROTEIN; MICONAZOLE; PROBIOTIC AGENT;

ADULT; ALEXANDER DISEASE; AMINO ACID SUBSTITUTION; ATAXIA; BLADDER DYSFUNCTION; CASE REPORT; CLINICAL FEATURE; DNA SEQUENCE; DYSARTHRIA; EXON; FEMALE; GENETIC ANALYSIS; HETEROZYGOSITY; HUMAN; LETTER; MINI MENTAL STATE EXAMINATION; MYOCLONUS; NUCLEAR MAGNETIC RESONANCE IMAGING; POINT MUTATION; SPEECH DISORDER; UNSPECIFIED SIDE EFFECT; VAGINITIS;

ADULT; ALEXANDER DISEASE; ANTI-BACTERIAL AGENTS; CEFTRIAXONE; EYE MOVEMENTS; FEMALE; HUMANS;

EID: 77649271362     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2009.11.021     Document Type: Letter

References (11)

1. Brenner M., Johnson A.B., Boesflug-Tanguy O., Rodriguez D., Goldman J.E., Messing A. Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease. Nat Genet 2001, 27:117-120.
2. Dell'Osso LF. Recording and Calibrating the Eye Movements of Nystagmus Subjects. OMLAB Report#011105, 1-4, 2005; http://www.omlab.org/OMLAB%20page/Teaching/teaching.html.
3. Li R., Salomons G., Johnson A.B., Naidu S., Goldman J.E., Quinlan R, et al. Glial fibrillary acidic protein mutations in infantile, juvenile and adult forms of Alexander disease. Ann Neurol 2005, 57:310-328.
4. Mignot C., Boespflug-Tanguy O., Gelot A., Dautigny A., Pham-Dinh D., Rodriguez D. Alexander disease: putative mechanisms of an astrocytic encephalopathy. CMLS, Cell Mol Life Sci 2004, 61:369-385.
5. Mignot C., Delarasse C., Eschaich S., Della Gaspera B., Noé E., Colucci-Guyon E., et al. Dynamics of mutated GFAP aggregates revealed by real-time imaging of an astrocyte model of Alexander disease. Exp Cell Res 2007, 313:2766-2779.
6. Quinlan R.A., Brenner M., Goldman J.E., Messing A. GFAP and its role in Alexander disease. Exp Cell Res 2007, 313:2077-2087.
7. Rothstein J.D., Patel S., Regan M.R., Haenggeli C., Huang Y.H., Bergles D.E., et al. β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005, 433:73-77.
8. Sechi G.P., Conti M., Sau G.F., Cocco G.A. Valproate-induced parkinsonism, glial cells and Alexander disease. Prog Neuro-Psychopharmacol Biol Psychiatry 2008, 32:1351-1352.
9. Sullivan S.M., Lee A., Björkman S.T., Meller S.M., Sullivan R.K., Poronnik P., et al. Cytoskeletal anchoring of GLAST determines susceptibility to brain damage. An identified role for GFAP. J Biol Chem 2007, 282:2914-2923.
10. Tanaka K.F., Takebayashi H., Yamazaki Y., Ono K., Naruse M., Iwasato T., et al. Murine model of Alexander disease: analysis of GFAP aggregate formation and its pathological significance. Glia 2007, 55:617-631.
11. Thöne-Reineke C., Neumann C., Namsolleck P., Schmerbach K., Krikov M., Schefe J.H., et al. The β-lactam antibiotic, ceftriaxone, dramatically improves survival, increases glutamate uptake and induces neurotrophins in stroke. J Hypertens 2008, 26:2426-2435.